Connect with us

Health Care

ResApp Health Ltd (ASX:RAP) – Tony Keating

Published

on

The CEO Mindset - Tony Keating, Chief Executive Officer and Managing Director at ResApp Health (ASX:RAP)

Tony Keating is the Chief Executive Officer and Managing Director at ResApp Health (ASX:RAP), a developer of digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease. ResApp is creating easy to use, affordable, clinically-validated and regulatory-cleared diagnostic tools that only require a smartphone. Their solutions are designed to be easily integrated into existing telehealth solutions and they are also working on apps to provide respiratory disease diagnosis and management directly to consumers and healthcare providers.

What’s your journey in becoming a CEO?
After completing my PhD at The University of Queensland, I moved to the US to work at the University of Maryland as a Postdoc. At UM I worked on research projects that were funded by the US DoD and NASA. After two years in Washington DC, I moved to Boston to join Exa Corporation. Over 90 manufacturers in the automotive and aerospace industry used Exa’s engineering software to optimise the performance of their products. At Exa, I started in research and moved quickly into a technical business development role, helping develop and execute our aerospace market entry strategy. I returned to Australia in 2010 and joined UniQuest, the commercialisation company of The University of Queensland. At UniQuest, I led the commercialisation of engineering technologies, including identification and development of opportunities as well as sourcing and negotiating transactions with investors and strategic partners. During that time, I acted as interim CEO for a number of start-up companies. In my portfolio were a number of biomedical engineering technologies, one of which was the technology that become ResApp. Working closely with Brian Leedman, Dr Udantha Abeyratne (the inventor of the technology) and Dr Paul Porter (our clinical partner), we spun the ResApp technology out of the university and raised the first round of funding by listing the company on the ASX.

Tell us a bit about your business and how you are commercialising?
ResApp is a digital health company that is focused on respiratory disease. Our core technology uses machine learning algorithms to analyse sounds (such as cough, breathing or snoring sounds) to screen for, diagnose and manage respiratory disease. By using sound, we are able to deploy our technology on an off-the-shelf smartphone, such as an Apple iPhone, without the need for any accessories or other hardware. Since starting the company, we have focused on generating the clinical data and achieving regulatory approvals for our technology. I’m pleased that we now have excellent clinical data from multiple clinical studies and have received CE Mark and TGA approval for two breakthrough products.

ResAppDx uses cough sounds to diagnose respiratory diseases such as pneumonia, asthma exacerbations and COPD exacerbations. It has been demonstrated in large clinical studies to identify these diseases at high sensitivity and specificity. ResAppDx is clinically valuable as a triage tool in traditional settings such as an emergency department, urgent care clinic or GP’s office where it can provide a rapid point-of-care result, but it is in telehealth where we have an extremely strong value proposition. We are able to provide telehealth clinicians with an accurate way to asses a patient’s lungs without a stethoscope or imaging which are obviously not available in the telehealth setting. We are working closely with telehealth providers, including our announced deals with Coviu and Phenix Health, to integrate our algorithms into their platforms to provide a seamless experience for both patients and clinicians.

SleepCheck is a direct-to-consumer screening tool for obstructive sleep apnoea. Sleep apnoea is a major health issue, with 3 in 10 men and 2 in 10 women suffering from sleep apnoea, and up to 80% of those with sleep apnoea being undiagnosed and therefore untreated. Untreated, sleep apnoea doesn’t only result in daytime tiredness, but increases your risk of heart disease significantly. To be diagnosed with sleep apnoea today takes multiple steps, including a referral and a sleep study which involves trying to sleep with multiple contact sensors (chest straps, EGC patches on your skull, etc.), typically in an unfamiliar environment. SleepCheck reduces the barriers to diagnosis, by placing your smartphone on your bedside table when you go to sleep, you wake up to a score which assesses your risk of sleep apnoea, advising you on the next steps you can take.

How are you managing with the current COVID-19 pandemic on both business and personal front?
COVID-19 has changed the way governments, providers and the general public think about healthcare. This pandemic has accelerated the growth of telehealth and remote monitoring of patients. Telehealth providers such as Ping An Good Doctor (China) and Teladoc (USA) have seen huge increases in the number of telehealth consultations so far this year. Our Australian telehealth partners, Coviu and Phenix Health, have seen exponential growth since the Australian government opened up Medicate rebates for telehealth here. With this growth comes the responsibility to deliver quality care and we fill a unique position in providing the only scalable solution for remote respiratory diagnosis. Without a way to know what is happening in a patient’s lungs it is difficult for a telehealth clinician to effectively diagnose a patient who has respiratory symptoms.

COVID-19 itself represents a challenge for the global medical community and there are a number of ways we can assist. We are exploring ways of identifying the virus itself through cough, but also see an immediate opportunity to assist in managing patients with COVID-19 remotely, by identifying mild patients (i.e. patients where the disease has not progressed to a lung infection) and keeping them at home, reducing the load on hospitals and other facilities.

Operationally, our business is working well under the current restrictions. Our team have used Slack for internal comms since we founded the company and continue to make great progress even with the team working from home. Travel restrictions certainly limit our in-person visits to customers and partners, however, like all businesses, we have moved most of our business development efforts online to platforms like Zoom. We recently employed a very experienced sales and marketing leader for Europe who is based in London which certainly increases our capability there.

Personally, I’m spending a lot of time on Zoom rather than in hotels, airports and airplanes. There have been a few Zoom interruptions from kids, but that seems to be something that everybody around the world is getting used to.

What’s the most exciting thing about running your business?
The things our team are able to achieve. Our team has grown quickly and has achieved major milestones such as regulatory approval and our first customer deals, while facing and overcoming some setbacks along the way. Very few companies globally have experience in the areas where we operate. Our small team has developed technology, clinical and regulatory strategies that put us in a very unique position of being one of the very few companies in the world who have achieved what we have achieved.

How do you measure success?
I’ll always measure success by the creating products we create that help patients. These products will help doctors better take care of their patients, or will empower patients themselves to make more informed decisions about their health. If we do this then we will deliver strong returns to our shareholders.

What do you think is the most important quality of being a CEO of a listed company?
Time management and communication. It’s important to ensure that I listen to our shareholders and communicate effectively with them, but also balance that with running the business, which is all about listening and communicating with our team.

What is your favourite book?
I don’t think I really have a favourite book, but the most recent book I finished was The Antidote: Inside the World of New Pharma by Barry Werth. The story of Vertex Pharmaceuticals, it describes the ups and downs of healthcare, especially when developing brand new and novel products, and the persistence required to be successful.

What message do you want to send to our readership in Asia?
ResApp has achieved much over the last 5 years, resulting in regulatory approvals for two products, ResAppDx, targeting clinical diagnosis of respiratory disease, and SleepCheck, targeting at-home self-assessment of obstructive sleep apnoea. Both of these products are entering huge global markets in 2020. While the COVID-19 pandemic has slowed global business growth, it has shone a spotlight on respiratory disease and telehealth.

How can people connect with you?
Email:
tony@resapphealth.com.au
ResApp Website: https://www.resapphealth.com.au/

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health Care

mPort and Springday – Dipra Ray

Published

on

The CEO Mindset - Dipra Ray, CEO of mPort and Springday

Dipra Ray is the CEO of mPort and Springday, the former being a health company specialising in 3D body mapping, to assist people on their wellbeing journeys while the latter is a corporate wellbeing organisation that develops bespoke programs for workplaces to keep their employees happy and engaged in their roles. The companies merged together at the end of 2019. 

What’s your journey in becoming a Chief Executive Officer?
I started my first business when I was in high school where I managed a network of really intelligent people who worked as tutors which gave me a strong foundation in being able to both hire and manage exceptional people. At university, I decided to pursue studies in Accounting and Finance as I thought would provide me with the base knowledge of how businesses operated and ended up completing an Honours in Finance. Post my Honours, I started my career as an investment banker with Deutsche Bank specialising in mergers and acquisitions. This gave me a broad base of commercial & capital markets knowledge and also the ability to work under high pressure environments. Post my stint at Deutsche, I founded mPort and was the first CEO there and have continued in that role since.

Tell us a bit about your business and how you are commercializing?
mPort and Springday are building clever ecosystems that help to improve the wellbeing of people. At mPort we do this via capturing accurate body measurements through our one-of-a-kind fully automated mPods that are located in most of Australia’s top shopping centres. People use our service to see how their bodies are changing over time and to keep themselves motivated on their fitness journey. Springday on the other hand provides corporates with a platform to help keep their staff engaged, happier and healthier. We work with businesses to build wellbeing journeys that are personalised, interesting and fun. We work with some of Australia’s leading businesses who are committed to improve the wellbeing of their people.

What’s the most exciting thing about running your business?
The most exciting part about running mPort & Springday is that we’re constantly growing and expanding both our products but also the range of industries and clients we service. Every week is an ability for us to continue building our product and create more value for our partners and customers. It’s also super exciting to see how we’ve been able to mature as a business and see the level of growth we’re generating for our own people.

How do you measure success?
Success = being happy 🙂

What do you think is the most important quality of being a CEO of a listed company?
The most important quality of being a CEO is to be able to set an achievable focused strategic vision and then focus ruthlessly on execution. Too many businesses set far too broad strategic visions or stumble when it comes to execution by getting distracted by anything new. Being disciplined and focused on one’s core strategies is really important for a high growth business.

What is your favourite book?
Liar’s Poker by Michael Lewis and Five Point Someone by Chetan Bhagat.

What message do you want to send to our readership in Asia & Australia?
Health and wellbeing will develop into a more sophisticated trend that what we’ve seen in the past few years. So far, the trend has been mainly focused on products such as health foods, dairy and alike. We’re seeing that shift as consumers become more aware of how important overall wellbeing is – both from an emotional and physical perspective. While emotional wellbeing still remains a taboo topic in a lot of Asian countries that will change as the younger generation demands better conditions and as the global workforce becomes more mobile. This is primarily why we see a huge opportunity to invest in wellbeing in the Asian markets.

How can people connect with you?
Linkedin: https://www.linkedin.com/in/dipra-ray/
mPort’s Website: https://mport.com/
Springday’s Website: https://myspringday.com.au/

Continue Reading

Health Care

Q&A With StockPal – Race Oncology (ASX:RAC)

Published

on

Q&A with StockPal - Dr. Daniel Tillett, Chief Scientific Officer (CSO) & Executive Director of Race Oncology (ASX:RAC)

Watch Dr. Daniel Tillett, Chief Scientific Officer (CSO) & Executive Director of Race Oncology (ASX:RAC), as he discusses the latest Israel AML Phase 2 Trial recently and the commencement of the Phase 2 Extramedullary AML Trial.

0:15 – Could you walk us through the latest announcement with regards to the Israel AML Phase 2 Trial Contract?
1:59 – Any reason for choosing Israel as the trial candidate, and which other countries were considered?
3:11 – When do you foresee Phase 3 to commence and what milestones must be achieved first?
5:16 – Lastly, could you also comment on the Phase 2 Extramedullary AML Trial commencement?

Visit RAC’s website to learn more about their story: https://www.raceoncology.com/

Email editor@stockpal.asia if you are or represent a listed-company and is keen to be in our interviews.

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Health Care

Q&A With StockPal – Exopharm (ASX:EX1)

Published

on

Q&A with StockPal - Chris Baldwin, Deputy CEO of Exopharm (ASX:EX1)

Watch Chris Baldwin, Deputy CEO of Exopharm (ASX:EX1), as he explains about the Exopharm’s latest developments and potential target markets.

0:00 – Intro

0:10 – What is your business about?

1:20 – Tell us about your product developments and pipeline?

3:01 – What is the size of your potential target markets?

4:16 – What is EX1’s competitive advantage?

5:30 – How did your company cope during the COVID-19 pandemic?

6:28 – How are you currently engaging with your investors?

Visit Exopharm’s website: https://exopharm.com/

Email editor@stockpal.asia if you are or represent a listed-company and is keen to be in our interviews.

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Get more stuff

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

Recent Posts

Categories

Trending